Dublin, Dec. 22, 2016 -- Research and Markets has announced the addition of the "Chronic Pain Drugs Price Analysis and Strategies - 2016" report to their offering.
Chronic Pain Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Chronic Pain market.
The research answers the following questions:
- What are the key drugs marketed for Chronic Pain and their clinical attributes? How are they positioned in the Global Chronic Pain market?
- What are the unit prices and annual treatment cost for Chronic Pain therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Chronic Pain drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Chronic Pain?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Chronic Pain including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Chronic Pain
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Chronic Pain market
- Chronic Pain Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Chronic Pain New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/p68dtk/chronic_pain
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Analgesics


Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 



